Clinical Trials for Aosaikang Pharmaceutical

Explore 7 clinical trials worldwide

Showing 1-7 of 7 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Aosaikang Pharmaceutical

Clinical Trials (7)

NCT07109531
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
PHASE3Not yet recruiting
286 participants
Started: Aug 31, 2025 · Completed: Dec 31, 2028
1 condition1 sponsor1 location
NCT06614608
The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain
PHASE1Not yet recruiting
24 participants
Started: Oct 31, 2024 · Completed: Dec 31, 2025
2 conditions1 sponsor1 location
NCT06206733
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
PHASE3Recruiting
780 participants
Started: Jan 25, 2024 · Completed: Dec 30, 2028
2 conditions2 sponsors1 location
NCT05867420
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
PHASE1Recruiting
104 participants
Started: Aug 3, 2023 · Completed: Dec 31, 2025
1 condition2 sponsors2 locations
NCT05632939
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
PHASE1/PHASE2Active, not recruiting
62 participants
Started: Feb 21, 2023 · Completed: Feb 10, 2026
2 conditions2 sponsors1 location
NCT04632108
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
PHASE1/PHASE2Active, not recruiting
199 participants
Started: Jan 28, 2021 · Completed: Dec 31, 2025
1 condition2 sponsors2 locations
NCT04143607
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
PHASE3Active, not recruiting
337 participants
Started: Jul 23, 2019 · Completed: Sep 30, 2026
1 condition1 sponsor3 locations